Category: Press Release

2024.09.16

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

2024.09.10

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

2024.08.28

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

2024.08.26

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

2024.08.07

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP(PwC)

2024.07.15

I-Mab Announces Leadership Transitions

2024.06.06

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

2024.06.05

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

2024.05.23

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

2024.05.22

I-Mab to Participate at the Jefferies Global Healthcare Conference